Company / Financials
Regen BioPharma Inc Financials
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$236.6K
FY2025 · +0.0% YoY
Net Income
-$1.3M
FY2025 · -90.7% YoY
Profit Margin
-538.8%
FY2025 · net income / revenue
ROE
-
FY2025 · return on equity
Total Assets
$274.6K
FY2025
Total Debt
-
FY2025
Equity
-$6.3M
FY2025
ROA
-464.1%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -86.67 (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$236.6K+0.0% YoYNet Income HistoryProfit after all expenses and taxes-$1.3M-90.7% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$338.5K+18.9% YoYSG&A Expense HistorySelling, general, and administrative expenses$75.1K+27.5% YoYR&D Expense HistoryResearch and development spending$11.7K-92.4% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$0.16-155.2% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.16-155.2% YoYShares Outstanding HistoryWeighted average diluted shares outstanding3.4M0.0% YoY